Furthermore, YTHDF2 orchestrates the reprogramming of tumor-associated macrophages in the tumor microenvironment (TME), and YTHDF2 is an effective target to enhance cancer immunotherapy (Ma et al., 2023). This evidence concerns the gene YTHDF2 and cancer.